Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
$855K Sell
27,625
-15,650
-36% -$533K 2.46% 22
2019
Q4
$1.61M Sell
43,275
-2,747
-6% -$97.8K 2.05% 28
2019
Q3
$1.57M Sell
46,022
-27,427
-37% -$997K 1.82% 31
2019
Q2
$3.02M Sell
73,449
-372
-0.5% -$14.8K 3.53% 3
2019
Q1
$2.98M Sell
73,821
-17,078
-19% -$684K 3.45% 3
2018
Q4
$3.76M Sell
90,899
-7,324
-7% -$304K 3.98% 1
2018
Q3
$4.11M Sell
98,223
-1,013
-1% -$39K 3.47% 3
2018
Q2
$3.42M Buy
99,236
+1,346
+1% +$46K 2.93% 5
2018
Q1
$3.3M Buy
97,890
+14,852
+18% +$511K 2.86% 5
2017
Q4
$2.85M Buy
+83,038
New +$2.83M 2.47% 14

Other funds holding PFE

MHI Funds's PFE Position: Q1 2020 in Review

MHI Funds reduced its Pfizer (PFE) stake by 36% in Q1 2020, selling an estimated $533K and leaving 27,625 shares worth $855K. The position accounts for 2.46% of the portfolio, ranked #22.

MHI Funds first reported a position in PFE in Q4 2017 and has held it in 10 quarters since. The position peaked at $4.11M in Q3 2018. 2,438 funds tracked by Wall St. Rank hold PFE as of Q1 2020.

  • MHI Funds held 27,625 shares of Pfizer worth $855K as of Q1 2020.
  • MHI Funds sold 15,650 Pfizer shares in Q1 2020, an estimated $533K.
  • Pfizer made up 2.46% of MHI Funds's portfolio in Q1 2020, its #22 holding.
  • MHI Funds first reported a position in Pfizer in Q4 2017 and has held it in 10 quarters since.
  • MHI Funds's Pfizer position peaked at $4.11M in Q3 2018.
  • 2,438 funds tracked by Wall St. Rank held Pfizer as of Q1 2020.

Based on MHI Funds's 13F filing for Q1 2020, filed 5 May 2020.